Clinical Trial

Autologous Stem Cell Transplantation for Patients With AL Amyloidosis

Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated February 26, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study mainly evaluated the efficacy and safety of autologous stem cell transplantation for the treatment of AL amyloidosis, the role of induction and maintenance therapy in autologous stem cell transplantation, and the long-term efficacy and prognosis risk factors of autologous stem cell transplantation for the treatment of AL amyloidosis.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2019-12-22; most recent amendment 2024-02-22.
Trial Details
NCT Number NCT04210791
Lead Sponsor Nanjing University School of Medicine
Conditions AL Amyloidosis, Plasma Cell Dyscrasia
Enrollment 500 participants
Start Date 2010-07-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-02-26